PCR versus Immunohistochemistry for Microsatellite Instability

Samowitz, Wade S.; Broaddus, Russell R.; Iacopetta, Barry; Goldblatt, Jack

doi:10.2353/jmoldx.2008.070147

Cited by 8 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Discordant results of immunohistochemistry and PCR-based techniques were observed in this study. Notably, it has been described that in some cases MSI can be detected via a PCR approach without concurrent loss of expression of any of the four mismatch repair proteins, as these have lost their function as a result of mutations [ 19 , 20 , 21 ]. Thus, discrepancies between the two methods have been described for other entities such as colorectal cancer, indicating to view these techniques as complimentary.…”

Section: Discussionmentioning

confidence: 99%

Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital

Winkelmann

Schneider

Hartmann

et al. 2018

IJMS

View full text Add to dashboard Cite

Immune-modulating therapy is a promising therapy for patients with cholangiocarcinoma (CCA). Microsatellite instability (MSI) might be a favorable predictor for treatment response, but comprehensive data on the prevalence of MSI in CCA are missing. The aim of the current study was to determine the prevalence of MSI in a German tertiary care hospital. Formalin-fixed paraffin-embedded tissue samples, obtained in the study period from 2007 to 2015 from patients with CCA undergoing surgical resection with curative intention at Johann Wolfgang Goethe University hospital, were examined. All samples were investigated immunohistochemically for the presence of MSI (expression of MLH1, PMS2, MSH2, and MSH6) as well as by pentaplex polymerase chain reaction for five quasimonomorphic mononucleotide repeats (BAT-25, BAT-26, NR-21, NR-22, and NR-24). In total, 102 patients were included, presenting intrahepatic (n = 35, 34.3%), perihilar (n = 42, 41.2%), and distal CCA (n = 25, 24.5%). In the immunohistochemical analysis, no loss of expression of DNA repair enzymes was observed. In the PCR-based analysis, one out of 102 patients was found to be MSI-high and one out of 102 was found to be MSI-low. Thus, MSI seems to appear rarely in CCA in Germany. This should be considered when planning immune-modulating therapy trials for patients with CCA.

show abstract

Section: Discussionmentioning

confidence: 99%

Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital

Winkelmann

Schneider

Hartmann

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…Each method is acceptable and has ∼90% sensitivity if performed alone; combining both methods increases the sensitivity .…”

Section: Practical Approach To Determine Testing Availabilitymentioning

confidence: 99%

Implementing Keytruda/Pembrolizumab Testing in Clinical Practice

Ratner

Lennerz

2018

The Oncologist

View full text Add to dashboard Cite

show abstract

“…This includes proficiency testing that assesses the correlation between MSI and IHC findings, which should be at least 95%, because errors in interpretation could occur, especially involving weak or patchy IHC staining. 35,36 Furthermore, an experienced genetic counselor and clinician should review the findings of both informative and uninformative cases to ensure that results of individual cases and the larger practice are consistent with expected values. Periodic updates of institutional performance are warranted for all involved clinicians.…”

Section: When To Test For Suspected Ls?mentioning

confidence: 99%

When and How to Perform Genetic Testing for Inherited Colorectal Cancer Syndromes

Lynch

2013

J Natl Compr Canc Netw

View full text Add to dashboard Cite

The 2013 NCCN Clinical Practice Guidelines in Oncology for Colorectal Cancer Screening address the evaluation and management of patients at risk of inherited susceptibility to colorectal cancer. These patients include the 2 broad categories of patients with familial adenomatous polyposis and its variants, and those with hereditary nonpolyposis colorectal cancer, or Lynch syndrome. This article provides a somewhat personal, yet hopefully evidence-based, approach to the questions of when to test individuals for inherited susceptibility, and how to do so. "When" can be taken to mean "under what circumstance" and "at what age"; this article attempts to speak to each sense of the term.

show abstract

PCR versus Immunohistochemistry for Microsatellite Instability

Cited by 8 publications

References 1 publication

Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital

Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital

Implementing Keytruda/Pembrolizumab Testing in Clinical Practice

When and How to Perform Genetic Testing for Inherited Colorectal Cancer Syndromes

Contact Info

Product

Resources

About